DOI QR코드

DOI QR Code

Clinical Study on Fluvoxamine Combined with Oxycodone Prolonged-Release Tablets in Treating Patients with Moderate to Severe Cancer Pain

  • Xiao, Yang (Department of Medical Oncology, The People's Hospital of Taixing City) ;
  • Liu, Jun (Department of Medical Oncology, The People's Hospital of Taixing City) ;
  • Huang, Xin-En (Department of Chemotherapy, the Affiliated Jiangsu Cancer Hospital of Nanjing Medical University & Jiangsu Institute of Cancer Research) ;
  • Ca, Li-Hua (Department of Medical Oncology, The People's Hospital of Taixing City) ;
  • Ma, Yi-Min (Department of Medical Oncology, The People's Hospital of Taixing City) ;
  • Wei, Wei (Department of Medical Oncology, The People's Hospital of Taixing City) ;
  • Zhang, Rong-Xia (Department of Medical Oncology, The People's Hospital of Taixing City) ;
  • Huang, Xiao-Hong (Department of Medical Oncology, The People's Hospital of Taixing City) ;
  • Chang, Juan (Department of Medical Oncology, The People's Hospital of Taixing City) ;
  • Wu, Yi-Jia (Department of Medical Oncology, The People's Hospital of Taixing City)
  • Published : 2015.01.06

Abstract

Objective: To observe treatment effects and safety of fluvoxamine combined with oxycodone prolonged-release tablets in treating patients with moderate to severe cancer pain. Methods: Patients confirmed pathologically with cancer and complicated with moderate to severe pain, were divided into control and experimental groups. Oxycodone prolonged-release tablets, with or without fluvoxamine, were administrated to all study patients until pain relief. Degree of pain relief, dose of oxycodone prolonged-release tablets, side effects and quality of life were compared before and after treatment. Results: In total, 120 patients were recruited. No statistically significant difference was detected regarding age, gender, types of cancer, KPS between two groups of patients (P>0.05). Baseline pain score of patients with moderate pain in treatment and control group was $4.9{\pm}0.8$ and $5.1{\pm}0.8$, respectively; and decreased to $1.8{\pm}1.1$ and $1.2{\pm}1.1$ after treatment, respectively. Pain intensity was significantly reduced in the treatment group (P=0.028). Average daily consumption of oxycodone prolonged-release tablets was ($54.0{\pm}19.6$) mg and ($44.7{\pm}18.7$) mg respectively, which is lower in treatment grpup than in control group, but the difference was not statistically significant (P=0.065). Baseline pain score of patients with severe pain in treatment and control groups were $8.3{\pm}1.1$ and $8.3{\pm}1.1$, respectively; and pain intensity after treatment decreased to $2.9{\pm}1.0$ and $2.3{\pm}1.0$. Pain intensity was significantly reduced in the treatment group, with statistical significance (P=0.026). Average daily consumption of oxycodone prolonged-release tablets was ($132.0{\pm}42.2$) mg and ($110.7{\pm}33.9$) mg, respectively, which is lower in treatment group than in control group, and the difference was statistically significant (P=0.035). In terms of quality of life, patients in treatment group had better performance status, daily activity, mood, and sleep than that in control group (P < 0.05). Patients in two groups had similar side effects, eg., constipation, nausea/vomiting, lethargy, dizziness, itchy skin, dysuria, and ataxia. Lower incidence of nausea/vomiting, lethargy, was obtained from patients in treatment than in control group, while significant low constipation was observed in treatment than in control group (35.0% vs 49.2%, P=0.026). Conclusion: Fluvoxamine combined with oxycodone prolonged-release tablets could be more effective in treating patients with cancer pain, and could reduce the dosage of oxycodone prolonged-release tablets and thus be associated with lower side effects, and improved quality of life.

Keywords

Cancer pain;fluvoxamine;oxycodone

References

  1. Liang SY, Chen KP, Tsay SL, et al (2013). Relationship between belief about analgesics, analgesic adherence and pain experience in Taiwanese cancer outpatients. Asian Pac J Cancer Prev, 14, 713-6. https://doi.org/10.7314/APJCP.2013.14.2.713
  2. Liang SY, Wang TJ, Wu SF, et al (2013). Gender differences associated with pain characteristics and treatment in Taiwanese oncology outpatients. Asian Pac J Cancer Prev, 14, 4077-82. https://doi.org/10.7314/APJCP.2013.14.7.4077
  3. Leow KP, Cramond T, Smith MT (1995). Pharmacokinetics and pharmacodynamics of oxycodone when given intravenously and rectally to adult patients with cancer pain. Anesth Analg, 80, 296-302.
  4. Merboth MK, Barnason S (2000). Managing pain: the fifth vital sign (J). Nurse Clin North AM,,, 35, 375-83.
  5. Meserve J R, Kaye A D, Prabhakar A, et al (2014). The role of analgesics in cancer propagation. Best Pract Res Clin Anaesthesiol, 28, 139-51. https://doi.org/10.1016/j.bpa.2014.04.004
  6. Mika J, Popiolek-Barczyk K, Rojewska E, et al (2014). Deltaopioid receptor analgesia is independent of microglial activation in a rat model of neuropathic pain. PLoS One, 9, e104420. https://doi.org/10.1371/journal.pone.0104420
  7. Shen H, Hu X, Szymusiak M, et al (2014). Orally administered nanocurcumin to attenuate morphine tolerance: comparison between negatively charged PLGA and partially and fully PEGylated nanoparticles. Mol Pharm, 10, 4556-51.
  8. Yang J, Yang H, Du X, et al (2014). Morphine and DAMGO produce an opposite effect on presynaptic glutamate release via different downstream pathways of ${\mu}$ opioid receptors in the basolateral amygdala. Neuropharmacology, 86C, 353-61.
  9. Davis MP, Walsh D (2004). Epidemiology of cancer pain and factors influencing poor pain contro1. Am J Hosp Palliat Care, 21, 137-42. https://doi.org/10.1177/104990910402100213
  10. Glare PA, Walsh TD (1993). Dose-ranging study of oxycodone for chronic pain in advanced cancer. J Clin Oncol, 11, 973-8.
  11. Kalso E, Poyhia R, Onnela I' et al (1991). Intravenous morphine and oxycodone for pain after abdominal surgery. Acta Anaesthesiol Stand, 35, 642-6. https://doi.org/10.1111/j.1399-6576.1991.tb03364.x

Cited by

  1. Opioids combined with antidepressants or antiepileptic drugs for cancer pain: Systematic review and meta-analysis pp.1477-030X, 2017, https://doi.org/10.1177/0269216317711826